About the author: Molly McGaughan is managing director for North America at Beyond. For decades, investors have chosen pharma stocks based largely on which companies have drugs and vaccines being sold to large numbers of people. Savvy shareholders in these companies have worked to avoid looming “patent cliffs”—the moments when exclusivity on popular therapies runs